Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Minor H, rather than MHC, alloantigens offer the greater barrier to successful orthotopic corneal transplantation in mice.
Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Blood-borne signals that induce anterior chamber-associated immune deviation after intracameral injection of antigen.
The effect of IL-12 on immune privilege of the eye.
Immune privilege to MHC-disparate tumor grafts in the anterior chamber of the eye. I. Quantitative analysis of intraocular tumor growth and the corresponding delayed hypersensitivity response.
Langerhans cells, orthotopic corneal allografts, and direct and indirect pathways of T-cell allorecognition.
Infiltration and accumulation of precursor cytotoxic T-cells increase with time in progressively growing ocular tumors.
Cell-mediated immune tolerance to HSV-1 antigens associated with reduced susceptibility to HSV-1 corneal lesions.
Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space.
Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.
Characterization of cell-mediated immune responses elicited by orthotopic corneal allografts in mice.
Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction.
Imposing deviant immunity on the presensitized state.
Evidence that active suppression contributes to the success of H-2-incompatible orthotopic corneal allografts in mice.
CELL-MEDIATED IMMUNE RESPONSE TO INTRAOCULAR TUMORS